{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:54:13Z","timestamp":1783947253701,"version":"3.55.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":713,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our main aim was to investigate the short-term therapeutic effects, safety\/tolerability and potential side effects of the cannabis galenical preparation (Bedrocan) in patients with a range of chronic conditions unresponsive to other treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective, \u2018compassionate use\u2019, observational, open-label study, 20 patients (age 18\u201380 years) who had appealed to our \u2018Second Opinion Medical Consulting Network\u2019 (Modena, Italy), were instructed to take sublingually the galenical oil twice a day for 3 months of treatment. The usual starting dose was low (0.5 ml\/day) and gradually titrated upward to the highest recommended dose (1 ml\/day). Tolerability and adverse effects were assessed at baseline and monthly thereafter during the treatment period through direct contact (email or telephone) or visit if required. Patients\u2019 quality of life was evaluated at baseline and 3 months using the medical outcome short-form health survey questionnaire (SF-36).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>From baseline to 6 months post-treatment, SF-36 scores showed: reductions in total pain (P &amp;lt; 0.03); improvements in the physical component (P &amp;lt; 0.02); vitality (P &amp;lt; 0.03); social role functioning (P &amp;lt; 0.02); and general health state (P &amp;lt; 0.02). No changes in role limitations (P = 0.02) due to emotional state (e.g. panic, depression, mood alteration) were reported. Monthly reports of psychoactive adverse effects showed significant insomnia reduction (P &amp;lt; 0.03) and improvement in mood (P &amp;lt; 0.03) and concentration (P &amp;lt; 0.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data suggest that a cannabis galenical preparation may be therapeutically effective and safe for the symptomatic treatment of some chronic diseases. Further studies on the efficacy of cannabis as well as cannabinoid system involvement in the pathophysiology are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/ijpp.12514","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T15:02:44Z","timestamp":1550242964000},"page":"264-270","source":"Crossref","is-referenced-by-count":13,"title":["Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan)"],"prefix":"10.1093","volume":"27","author":[{"given":"Beniamino","family":"Palmieri","sequence":"first","affiliation":[{"name":"Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy"},{"name":"Second Opinion Medical Network, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Laurino","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy"},{"name":"Second Opinion Medical Network, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-5072","authenticated-orcid":false,"given":"Maria","family":"Vadal\u00e0","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy"},{"name":"Second Opinion Medical Network, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"2021031319195630800_ijpp12514-bib-0001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/j.1552-4604.1975.tb02348.x","article-title":"Analgesic effect of delta-9-tetrahydrocannabinol","volume":"15","author":"Noyes","year":"1975","journal-title":"J Clin Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0002","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1533-2500.2010.00427.x","article-title":"An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy","volume":"11","author":"Bestard","year":"2010","journal-title":"Pain Pract"},{"key":"2021031319195630800_ijpp12514-bib-0003","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/jpm.2014.9431","article-title":"Cannabis for symptom control","volume":"17","author":"Aggarwal","year":"2014","journal-title":"J Palliat Med"},{"issue":"11","key":"2021031319195630800_ijpp12514-bib-0004","first-page":"CD009464","article-title":"Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021031319195630800_ijpp12514-bib-0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0885-3924(97)00038-9","article-title":"Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia","volume":"14","author":"Beal","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"2021031319195630800_ijpp12514-bib-0006","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.ijg.0000212260.04488.60","article-title":"Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study","volume":"15","author":"Tomida","year":"2006","journal-title":"J Glaucoma"},{"key":"2021031319195630800_ijpp12514-bib-0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/294264","article-title":"Treatment of Tourette syndrome with cannabinoids","volume":"27","author":"Muller-Vahl","year":"2012","journal-title":"Behav Neurol"},{"key":"2021031319195630800_ijpp12514-bib-0008","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.lfs.2005.05.055","article-title":"Cannabinoid signaling","volume":"78","author":"Demuth","year":"2006","journal-title":"Life Sci"},{"key":"2021031319195630800_ijpp12514-bib-0009","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/3-540-26573-2_15","article-title":"Cannabinoid function in learning, memory and plasticity","author":"Riedel","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"2021031319195630800_ijpp12514-bib-0011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neulet.2005.11.038","article-title":"Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study","volume":"396","author":"Ashton","year":"2006","journal-title":"Neurosci Lett"},{"key":"2021031319195630800_ijpp12514-bib-0012","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/syn.20050","article-title":"Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study","volume":"53","author":"Nunez","year":"2004","journal-title":"Synapse"},{"key":"2021031319195630800_ijpp12514-bib-0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12974-017-0960-0","article-title":"Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y12 and P2Y13 receptors in neuropathic pain rats","volume":"14","author":"Niu","year":"2017","journal-title":"J Neuroinflammation"},{"key":"2021031319195630800_ijpp12514-bib-0014","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1213\/ANE.0000000000002110","article-title":"Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis","volume":"125","author":"Meng","year":"2017","journal-title":"Anest Analg"},{"key":"2021031319195630800_ijpp12514-bib-0015","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1213\/ANE.0000000000002513","article-title":"Unraveling the mystery of THC: cannabinoids and neuropathic pain","volume":"125","author":"Naveen","year":"2017","journal-title":"Anest Analg"},{"key":"2021031319195630800_ijpp12514-bib-0016","volume-title":"Cannabis: the scientific and medical evidence","author":"House of Lords Select Committee on Science and Technology","year":"1998"},{"key":"2021031319195630800_ijpp12514-bib-0017","volume-title":"Product monograph: Sativex\u00ae","author":"GW Pharma Ltd.","year":"2007"},{"key":"2021031319195630800_ijpp12514-bib-0018","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0091-3057(91)90384-E","article-title":"The pharmacologic effects of daily marijuana smoking in humans","volume":"40","author":"Perez-Reyes","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"2021031319195630800_ijpp12514-bib-0019","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol Ther"},{"key":"2021031319195630800_ijpp12514-bib-0021","volume-title":"The Science of Marijuana","author":"Iversen","year":"2008","edition":"2nd edn"},{"key":"2021031319195630800_ijpp12514-bib-0022","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","article-title":"Emerging strategies for exploiting cannabinoid receptor agonists as medicines","volume":"156","author":"Pertwee","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0023","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","article-title":"A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol","volume":"66","author":"Russo","year":"2006","journal-title":"Med Hypotheses"},{"key":"2021031319195630800_ijpp12514-bib-0024","volume-title":"Cannabidiol","author":"Grotenhermen","year":"2015"},{"issue":"3","key":"2021031319195630800_ijpp12514-bib-0025","first-page":"180","article-title":"Medicinal cannabis: History, pharmacology, and implications for the acute care","volume":"42","author":"Bridgeman","year":"2017","journal-title":"P T"},{"key":"2021031319195630800_ijpp12514-bib-0026","first-page":"1","volume-title":"Pharmacy Preparations European quality standards and regulation","author":"Scheepers","year":"2017"},{"key":"2021031319195630800_ijpp12514-bib-0027","first-page":"1161","article-title":"Medical use of cannabis: Italian and European legislation","volume":"22","author":"Zaami","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2021031319195630800_ijpp12514-bib-0028","volume-title":"GU Serie Generale n.279 del 30-11-2015","author":"Law: Decreto 9 novembre","year":"2015"},{"key":"2021031319195630800_ijpp12514-bib-0029","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem Biodivers"},{"key":"2021031319195630800_ijpp12514-bib-0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1300\/J175v03n01_02","article-title":"Clinical pharmacokinetics of cannabinoids","volume":"3","author":"Grotenhermen","year":"2003","journal-title":"J Cannabis Ther"},{"key":"2021031319195630800_ijpp12514-bib-0031","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/clpt.1983.179","article-title":"Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women","volume":"34","author":"Wall","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"2021031319195630800_ijpp12514-bib-0032","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007691-200608000-00010","article-title":"\u03949-Tetrahydrocannabinol, 11-Hydroxy-\u03949-Tetrahydrocannabinol and 11-Nor-9-Carboxy-\u03949-Tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids","volume":"28","author":"Goodwin","year":"2006","journal-title":"Ther Drug Monit"},{"key":"2021031319195630800_ijpp12514-bib-0033","first-page":"1","volume-title":"Medical marijuana: the state of the science","author":"Schatman","year":"2015"},{"key":"2021031319195630800_ijpp12514-bib-0034","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1503\/cmaj.110837","article-title":"Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial","volume":"184","author":"Corey-Bloom","year":"2012","journal-title":"CMAJ"},{"key":"2021031319195630800_ijpp12514-bib-0035","doi-asserted-by":"crossref","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ"},{"key":"2021031319195630800_ijpp12514-bib-0036","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jpain.2007.12.010","article-title":"A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain","volume":"9","author":"Wilsey","year":"2008","journal-title":"J Pain"},{"key":"2021031319195630800_ijpp12514-bib-0037","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1352458505070618","article-title":"Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis","volume":"12","author":"Wade","year":"2006","journal-title":"Mult Scler"},{"key":"2021031319195630800_ijpp12514-bib-0038","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","article-title":"Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up","volume":"76","author":"Zajicek","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021031319195630800_ijpp12514-bib-0039","first-page":"3","article-title":"The role of second opinion in oncology: an update","volume":"18","author":"Wunsch","year":"2013","journal-title":"Eur J Oncol"},{"key":"2021031319195630800_ijpp12514-bib-0040","first-page":"1","article-title":"The \u201cSecond Opinion Medical Network\u201d","volume":"3","author":"Palmieri","year":"2017","journal-title":"Int J Pathol Clin Res"},{"key":"2021031319195630800_ijpp12514-bib-0041","first-page":"575","article-title":"Second opinion clinic: is the Web Babel Syndrome treatable?","volume":"162","author":"Palmieri","year":"2011","journal-title":"Clin Ter"},{"key":"2021031319195630800_ijpp12514-bib-0042","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pec.2011.02.019","article-title":"The Web Babel syndrome","volume":"85","author":"Palmieri","year":"2011","journal-title":"Patient Educ Couns"},{"key":"2021031319195630800_ijpp12514-bib-0043","first-page":"1051","article-title":"The economic impact of second opinion in pathology","volume":"33","author":"Di Cerbo","year":"2012","journal-title":"Saudi Med J"},{"key":"2021031319195630800_ijpp12514-bib-0044","volume-title":"GU Serie Generale n.38 del 15.03.2010 describing the dispositions on palliative therapy access and pain therapy","author":"Law: Decreto 15 Marzo","year":"2010"},{"key":"2021031319195630800_ijpp12514-bib-0045","first-page":"79","article-title":"Short-term efficacy of CBD-enriched hemp oil in girls with dysautonomic syndrome after human papillomavirus vaccination","volume":"19","author":"Palmieri","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"2021031319195630800_ijpp12514-bib-0046","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36)","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2021031319195630800_ijpp12514-bib-0047","volume-title":"ICH harmonised tripartite guideline","author":"ICH Steering Committee","year":"1994"},{"key":"2021031319195630800_ijpp12514-bib-0048","volume-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2015"},{"key":"2021031319195630800_ijpp12514-bib-0049","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jphp.12845","article-title":"Cannabinoids concentration variability in cannabis olive oil galenic preparations","volume":"70","author":"Carcieri","year":"2018","journal-title":"J Pharm Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0050","doi-asserted-by":"crossref","first-page":"e18440","DOI":"10.1371\/journal.pone.0018440","article-title":"Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life","volume":"6","author":"Fiz","year":"2011","journal-title":"PLoS One"},{"key":"2021031319195630800_ijpp12514-bib-0051","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3233\/JAD-140093","article-title":"The potential therapeutic effects of THC on Alzheimer\u2019s disease","volume":"42","author":"Cao","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"2021031319195630800_ijpp12514-bib-0052","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-079X.2011.00864.x","article-title":"Melatonin treatment restores mitochondrial function in Alzheimer\u2019s mice: amitochondrial protective role of melatonin membrane receptor signaling","volume":"51","author":"Dragicevic","year":"2011","journal-title":"J Pineal Res"},{"key":"2021031319195630800_ijpp12514-bib-0053","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.nbd.2013.06.016","article-title":"Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors","volume":"59","author":"Mecha","year":"2013","journal-title":"Neurobiol Dis"},{"key":"2021031319195630800_ijpp12514-bib-0054","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrc3247","article-title":"Towards the use of cannabinoids as antitumour agents","volume":"12","author":"Velasco","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2021031319195630800_ijpp12514-bib-0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11481-015-9608-y","article-title":"The antitumour activity of plant-derived non-psychoactive cannabinoids","volume":"10","author":"McAllister","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0056","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy","volume":"171","author":"Ward","year":"2014","journal-title":"Br J Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0057","first-page":"1","article-title":"Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine","volume":"1","author":"Romano","year":"2013","journal-title":"Cannabinoids"},{"key":"2021031319195630800_ijpp12514-bib-0058","doi-asserted-by":"crossref","first-page":"130","DOI":"10.15252\/embr.201439742","article-title":"Medicinal use of cannabis in Europe","volume":"16","author":"Bifulco","year":"2015","journal-title":"EMBO Rep"},{"key":"2021031319195630800_ijpp12514-bib-0059","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1248\/cpb.58.201","article-title":"Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor","volume":"58","author":"Fischedick","year":"2010","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2021031319195630800_ijpp12514-bib-0060","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2021031319195630800_ijpp12514-bib-0061","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/02791072.1998.10399689","article-title":"Abuse potential of dronabinol (Marinol)","volume":"30","author":"Calhoun","year":"1998","journal-title":"J Psychoactive Drugs"},{"key":"2021031319195630800_ijpp12514-bib-0062","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1526-4637.2006.00085.x","article-title":"Experience with the synthetic cannabinoid nabilone in chronic noncancer pain","volume":"7","author":"Berlach","year":"2006","journal-title":"Pain Med"},{"key":"2021031319195630800_ijpp12514-bib-0063","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S1928","article-title":"Cannabinoids in the management of difficult to treat pain","volume":"4","author":"Russo","year":"2008","journal-title":"Ther Clin Risk Manag"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijpp.12514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijpp.12514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijpp.12514","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ijpp\/article-pdf\/27\/3\/264\/36596493\/ijpp12514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijpp\/article-pdf\/27\/3\/264\/36596493\/ijpp12514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T19:21:34Z","timestamp":1615663294000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/27\/3\/264\/6099731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,15]]},"published-print":{"date-parts":[[2019,5,21]]}},"URL":"https:\/\/doi.org\/10.1111\/ijpp.12514","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,2,15]]}}}